We have located links that may give you full text access.
CASE REPORTS
JOURNAL ARTICLE
Tc-99m-PSMA imaging allows successful radioguided surgery in recurrent prostate cancer.
Hellenic Journal of Nuclear Medicine 2018 September
OBJECTIVE: The introduction of the prostate specific membrane antigen (PSMA) offers the possibility to discover prostate cancer recurrences being frequently so small that they cannot be detected by conventional imaging modalities, such as magnetic resonance or computed tomography.
SUBJECTS AND METHODS: A 78 years old patient after radical prostatectomy and lymphadenectomy suffered from recurrence of the disease and galium-68-PSMA (68 Ga-PSMA) showed a single hot spot. Therefore, the first time in this indication in Austria radioguided surgery was performed after application of technetium-99m (99m Tc)-PSMA, which confirmed the single lesion already shown by 68 Ga-PSMA.
RESULTS: The lymph node was located dorsal to the urinary bladder dome in the presacral area, where normally no lymphadenectomy is performed, he was identified by the probe and removed. Postoperatively PSA-monitoring showed a decline from 13,1ng/mL (preoperatively) to <0,1ng/mL within 1 month.
CONCLUSION: The use of radiolabeled PSMA (primary diagnosis with 68 Ga, radioguided surgery with 99m Tc and finally treatment with 177 Lu) seems to be a major breakthrough in diagnosis and treatment of prostate cancer.
SUBJECTS AND METHODS: A 78 years old patient after radical prostatectomy and lymphadenectomy suffered from recurrence of the disease and galium-68-PSMA (68 Ga-PSMA) showed a single hot spot. Therefore, the first time in this indication in Austria radioguided surgery was performed after application of technetium-99m (99m Tc)-PSMA, which confirmed the single lesion already shown by 68 Ga-PSMA.
RESULTS: The lymph node was located dorsal to the urinary bladder dome in the presacral area, where normally no lymphadenectomy is performed, he was identified by the probe and removed. Postoperatively PSA-monitoring showed a decline from 13,1ng/mL (preoperatively) to <0,1ng/mL within 1 month.
CONCLUSION: The use of radiolabeled PSMA (primary diagnosis with 68 Ga, radioguided surgery with 99m Tc and finally treatment with 177 Lu) seems to be a major breakthrough in diagnosis and treatment of prostate cancer.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app